Advanced search
Publication Cover
Aging Health Volume 7, 2011 - Issue 4
Journal homepage
83
Views
0
CrossRef citations to date
0
Altmetric
Review

Polymyalgia Rheumatica and Giant Cell Arteritis: Management of Two Diseases of the Elderly

Christian Dejaco1 Department of Rheumatology & Immunology, Medical University of Graz, Auenbruggerplatz 2/4, A-8036 Graz, Austria
,
Christina Duftner2 Department of Internal Medicine, Bezirkskrankenhaus Kufstein, Endach 27, A-6330Kufstein, Austria
,
Bhaskar Dasgupta3 Department of Rheumatology, Southend University Hospital, Essex, UK
,
Eric L Matteson4 Division of Rheumatology & Division of Epidemiology, Departments of Internal Medicine & Health Sciences Research Mayo Clinic College of Medicine, Rochester, MN, USA
&
Michael Schirmer5 Department of Internal Medicine I, Innsbruck Medical University, Anichstrasse 35, A-6020Innsbruck, Austria.Correspondence[email protected]
Pages 633-645 | Published online: 12 Aug 2011

Bibliography

  • Weyand CM , GoronzyJJ. Giant-cell arteritis and polymyalgia rheumatica. Ann. Intern. Med.139 , 505–515 (2003).
  • Doran MF , CrowsonCS, O‘FallonWM, HunderGG, GabrielSE. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted county, Minnesota, USA. J. Rheumatol.29 , 1694–1697 (2002).
  • Crowson CS , MattesonEL, MyasoedovaE et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthr. Rheum. 63 , 633–639 (2011).
  • Bernatsky S , JosephL, PineauCA et al. Polymyalgia rheumatica prevalence in a population-based sample. Arthr. Rheum. 61 , 1264–1267 (2009).
  • Kermani TA , SchäferVS, CrowsonCS et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann. Rheum. Dis. 69 , 780–781 (2010).
  • Weyand CM , GoronzyJJ. Medium- and large-vessel vasculitis. N. Engl. J. Med.349 , 160–169 (2003).
  • Weyand CM , YoungeBR, GoronzyJJ. T cells in arteritis and atherosclerosis. Curr. Opin. Lipidol.19 , 469–477 (2008).
  • Krupa WM , DewanM, JeonMS et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am. J. Pathol. 161 , 1815–1823 (2002).
  • Ma-Krupa W , JeonMS, SpoerlS, TedderTF, GoronzyJJ, WeyandCM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J. Exp. Med.199 , 173–183 (2004).
  • Weyand CM , TetzlaffN, BjornssonJ, BrackA, YoungeB, GoronzyJJ. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum.40 , 19–26 (1997).
  • Deng J , YoungeBR, OlshenRA, GoronzyJJ, WeyandCM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation121 , 906–915 (2010).
  • Weyand CM , Ma-KrupaW, GoronzyJJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun. Rev.3 , 46–53 (2004).
  • Salvarani C , CantiniF, HunderGG. Polymyalgia rheumatica and giant-cell arteritis. Lancet372 , 234–245 (2008).
  • Blockmans D , De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford)46(4) , 672–677 (2007).
  • Wagner AD , DejacoC. Emergencies in rheumatology: giant cell arteritis with visual symptoms, vertebrobasilar insufficiency or other ischaemic complications. Aktuel. Rheumatol.35 , 43–48 (2010).
  • Dasgupta B , BorgFA, HassanN et al. BSR and BHPR standards, guidelines and audit working group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 49 , 1594–1597 (2010).
  • Mukhtyar C , GuillevinL, CidMC et al. EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 68(3) , 318–323 (2009).
  • Cimmino MA , ParodiM, ZampognaG, BarbieriF, GarlaschiG. Polymyalgia rheumatica is associated with extensor tendon tenosynovitis but not with synovitis of the hands: a magnetic resonance imaging study. Rheumatology50 , 494–499 (2011).
  • Salvarani C , CantiniF, BoiardiL, HunderGG. Polymyalgia rheumatica and giant-cell arteritis. N. Engl J. Med.347 , 261–271 (2002).
  • Nesher G , NesherR, RozenmanY, SonnenblickM. Visual hallucinations in giant cell arteritis: association with visual loss. J. Rheumatol.28 , 2046–2048 (2001).
  • Gonzalez-Gay MA , Vazquez-RodriguezTR, Gomez-AceboI et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 88 , 227–235 (2009).
  • Schmidt WA , SeifertA, Gromnica-IhleE, KrauseA, NatuschA. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford).47 , 96–101 (2008).
  • Blockmans D , de Ceuninck L, Vanderschueren S et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthr. Rheum.55 , 131–137 (2006).
  • Evans JM , O‘FallonWM, HunderGG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann. Intern. Med.122 , 502–507 (1995).
  • Gonzalez-Gay MA , Garcia-PorruaC, PineiroA, Pego-ReigosaR, LlorcaJ, HunderGG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine83 , 335–341 (2004).
  • García-Martínez A , Hernández-RodríguezJ, ArguisP et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthr. Rheum. 59 , 422–430 (2008).
  • Schmidt WA , MollA, SeifertA, SchickeB, Gromnica-IhleE, KrauseA. Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford)47 , 1406–1408 (2008).
  • Klein RG , HunderGG, StansonAW, ShepsSG. Large artery involvement in giant cell (temporal) arteritis. Ann. Intern. Med.83 , 806–812 (1975).
  • Godoy P , Araujo Sde A, Paulino E Jr, Lana-Peixoto MA. Coronary giant cell arteritis and acute myocardial infarction. Arq. Bras. Cardiol.88 , e84–e87 (2007).
  • Kalimanovska-Ostric DV , Simic-OgrizovicSP, Bonaci-NikolicBM, BozicVD, OstricVZ, DavidovicLB. Heart and renal failure in renovascular hypertension caused by giant cell arteritis – case report. Clin. Nephrol.67 , 58–60 (2007).
  • Sujobert P , FardetL, MarieI et al. Mesenteric ischemia in giant cell arteritis: 6 cases and a systematic review. J. Rheumatol. 34(8) , 1727–1732 (2007).
  • Brack A , Martinez-TaboadaV, StansonA, GoronzyJJ, WeyandCM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthr. Rheum.42 , 311–317 (1999).
  • Assie C , JanvresseA, PlissonnierD, LevesqueH, MarieI. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients. Medicine (Baltimore)90 , 40–51 (2011).
  • Kermani TA , WarringtonKJ. Lower extremity vasculitis in polymyalgia rheumatica and giant cell arteritis. Curr. Opin. Rheumatol.23(1) , 38–42 (2011).
  • Caselli RJ , DaubeJR, HunderGG, WhisnantJP. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology38 , 685–689 (1988).
  • Dasgupta B , CimminoM, Maradit-KremersH et al. Development of classification criteria for polymyalgia rheumatica (PMR): results from an international, prospective, multi-center longitudinal study. Arthr. Rheum. 62 , S689 (2010).
  • Chuang TY , HunderGG, IlstrupDM, KurlandLT. Polymyalgia rheumatica: a 10-year epidemiologicand clinical study. Ann. Intern. Med.97 , 672–680 (1982).
  • Healey LA . Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin. Arthritis Rheum.13 , 322–328 (1984).
  • Bird HA , EsselinckxW, DixonAS, MowatAG, WoodPH. An evaluation of criteria for polymyalgia rheumatica. Ann. Rheum. Dis.38 , 434–439 (1979).
  • Jones JG , HazlemanBL. Prognosis and management of polymyalgia rheumatica. Ann. Rheum. Dis.40 , 1–5 (1981).
  • Proven A , GabrielSE, O‘FallonWM, HunderGG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J. Rheumatol.26 , 1333–1337 (1999).
  • Helfgott SM , KievalRI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthr. Rheum.39 , 304–307 (1996).
  • Cantini F , SalvaraniC, OlivieriI et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthr. Rheum. 44 , 1155–1159 (2001).
  • Cantini F , SalvaraniC, OlivieriI et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin. Arthr. Rheum. 30 , 17–24 (2000).
  • Dasgupta B , HutchingsA, HollywoodJ, NutterL. Autoantibodies to cyclic citrullinated peptide in a PMR inception cohort from the PMR outcomes study. Ann. Rheum. Dis.67 , 903–904 (2008).
  • Dejaco C , KlotzW, LarcherH, DuftnerC, SchirmerM, HeroldM. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res. Ther.8 , R119 (2006).
  • Lopez-Hoyos M , Ruiz de Alegria C, Blanco R et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology43 , 655–657 (2004).
  • Kawasaki A , PurvinV. Giant cell arteritis: an updated review. Acta Ophthalmol.87 , 13–32 (2009).
  • Salvarani C , BarozziL, CantiniF et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann. Rheum. Dis. 67 , 758–761 (2008).
  • Falsetti P , AcciaiC, VolpeA, LenziL. Ultrasonography in early assessment of elderly patients with polymyalgic symptoms: a role in predicting diagnostic outcome? Scand. J. Rheumatol.40 , 57–63 (2011).
  • Dasgupta B , CimminoM, Maradit-KremersH et al. Utility of ultrasound in the diagnostic assessment of patients with shoulder pain in evaluation for polymyalgia rheumatica: results from an international, prospective, multi-center longitudinal study. Arthr. Rheum. 62 , S682 (2010).
  • Hunder GG , BlochDA, MichelBA et al. The American college of rheumatology 1990 criteria for the classification of giant cell arteritis. Arthr. Rheum. 33 , 1122–1128 (1990).
  • Younge BR , CookBE Jr, Bartley GB, Hodge DO, Hunder GG. Initiation of glucocorticoid therapy: before or after temporal artery biopsy? Mayo Clin. Proc.79 , 483–491 (2004).
  • Breuer GS , NesherR, NesherG. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin. Exp. Rheumatol.27(1 Suppl. 52) , S10–S13 (2009).
  • Boyev LR , MillerNR, GreenWR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am. J. Ophthalmol.128 , 211–215 (1999).
  • Ball EL , WalshSR, TangTY, GohilR, ClarkeJM. Role of ultrasonography in the diagnosis of temporal arteritis. Br. J. Surg.97 , 1765–1771 (2010).
  • Arida A , KyprianouM, KanakisM, SfikakisPP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet. Disord.11 , 44 (2010).
  • Pipitone N , VersariA, SalvaraniC. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology47 , 403–408 (2008).
  • Bley TA , UhlM, VenhoffN, ThodenJ, LangerM, MarklM. 3-T MRI reveals cranial and thoracic inflammatory changes in giant cell arteritis. Clin. Rheumatol.26 , 448–450 (2007).
  • Wenger M , GasserR, DonnemillerE et al. Images in cardiovascular medicine. Generalized large vessel arteritis visualized by 18fluorodeoxyglucose-positron emission tomography. Circulation 107(6) , 923 (2003).
  • Blockmans D , CoudyzerW, VanderschuerenS et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford) 47(8) , 1179–1184 (2008).
  • Hautzel H , SanderO, HeinzelA, SchneiderM, MüllerHW. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J. Nucl. Med.49 , 1107–1113 (2008).
  • Hernández-Rodríguez J , CidMC, López-SotoA, Espigol-FrigoléG, BoschX. Treatment of polymyalgia rheumatica: a systematic review. Arch. Intern. Med.169(20) , 1839–1850 (2009).
  • Dasgupta B , BorgFA, HassanN et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49(1) , 186–190 (2010).
  • Schmidt WA , Gromnica-IhleE, CasparyL, StieglerH. Polymyalgia rheumatica und riesenzellarteriitis (arteriitis temporalis). In: Rationelle Diagnostik und Therapie in der Inneren Medizin: Leitlinien. Dierkesmann R, Fleig WE, Heidrich H et al. (Eds). Elsevier, Urban & Fischer, Munich, Germany (2006).
  • Mackie SL , HensorEM, HaugebergG, BhaktaB, PeaseCT. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford)49 , 716–722 (2010).
  • Hutchings A , HollywoodJ, LampingDL et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthr. Rheum. 57(5) , 803–809 (2007).
  • Dasgupta B , DolanAL, PanayiGS, FernandesL. An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br. J. Rheumatol.37(2) , 189–195 (1998).
  • Mazlumzadeh M , HunderGG, EasleyKA et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthr. Rheum. 54 , 3310–3318 (2006).
  • Spies CM , BurmesterGR, ButtgereitF. Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica. Clin. Exp. Rheumatol.28(5 Suppl. 61) , S172–S177 (2010).
  • Mahr AD , JoverJA, SpieraRF et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthr. Rheum. 56 , 2789–2797 (2007).
  • De Silva M , HazlemanBL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann. Rheum. Dis.45 , 136–138 (1986).
  • Schaufelberger C , AnderssonR, NordborgE. No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br. J. Rheumatol.37 , 464–465 (1998).
  • Schaufelberger C , MöllbyH, UddhammarA, BrattJ, NordborgE. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand. J. Rheumatol.35 , 327–329 (2006).
  • Sailler L , Lapeyre-MestreM, GeffrayL et al. Adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis. A double blind randomized controlled trial. Arthr. Rheum. 61 , S1972 (2009).
  • Hoffman GS , CidMC, Rendt-ZagarKE et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann. Intern. Med. 146 , 621–630 (2007).
  • Salvarani C , MacchioniP, ManziniC et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann. Intern. Med. 146(9) , 631–639 (2007).
  • Kreiner F , GalboH. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthr. Res. Ther.12 , R176 (2010).
  • Catanoso MG , MacchioniP, BoiardiL, PipitoneN, SalvaraniC. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthr. Rheum.57(8) , 1514–1519 (2007).
  • Martínez-Taboada VM , Rodríguez-ValverdeV, CarreñoL et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann. Rheum. Dis. 67(5) , 625–630 (2008).
  • Mayrbaeurl B , HinterreiterM, BurgstallerS, WindpesslM, ThalerJ. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin. Rheumatol.26(9) , 1597–1598 (2007).
  • Bhatia A , EllPJ, EdwardsJC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann. Rheum. Dis.64(7) , 1099–1100 (2005).
  • Berger CT , WolbersM, MeyerP, DaikelerT, HessC. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology48 , 258–261 (2009).
  • Narváez J , BernadB, Gómez-VaqueroC et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin. Exp. Rheumatol. 26(3 Suppl. 49) , S57–S62 (2008).
  • Lee MS , SmithSD, GalorA, HoffmanGS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthr. Rheum.54 , 3306–3309 (2006).
  • Nesher G , BerkunY, MatesM, BarasM, RubinowA, SonnenblickM. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthr. Rheum.50 , 1332–1337 (2004).
  • Duftner C , DejacoC, SchirmerM. Polymyalgia rheumatica. Internist50 , 51–57 (2009).
  • Cimmino MA , SalvaraniC, MacchioniP et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin. Exp. Rheumatol. 26 , 395–400 (2008).
  • Narváez J , Nolla-SoléJM, ClavagueraMT, Valverde-GarcíaJ, Roig-EscofetD. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J. Rheumatol.26(9) , 1945–1952 (1999).
  • Pountain G , HazlemanB. Erythrocyte sedimentation rate (ESR) at presentation is a prognostic indicator for duration of treatment in polymyalgia rheumatica (PMR) Br. J. Rheumatol.36(4) , 508–509 (1997).
  • Dolan AL , MonizC, DasguptaB et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthr. Rheum. 40(11) , 2022–2029 (1997).
  • Pulsatelli L , BoiardiL, PignottiE et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk. Arthr. Rheum. 59(8) , 1147–1154 (2008).
  • Salvarani C , CantiniF, NiccoliL et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthr. Rheum. 53 , 33–38 (2005).
  • Schreiber S , BuyseM. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica. Clin. Rheumatol.14(3) , 315–318 (1995).
  • Weyand CM , FulbrightJW, EvansJM, HunderGG, GoronzyJJ. Corticosteroid requirements in polymyalgia rheumatica. Arch. Intern. Med.159(6) , 577–584 (1999).
  • Dejaco C , Wipfler-FreißmuthE, DuftnerC, SchirmerM. Assessment of disease activity of systemic vasculitides in clinical practice. Aktuel. Rheumatol.34 , 180–185 (2009).
  • Borg FA , DasguptaB. Treatment and outcomes of large vessel arteritis. Best. Prac. Res. Clin. Rheumatol.23 , 325–337 (2009).
  • Makkuni D , BharadwajA, WolfeK et al. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology 47 , 488–490 (2008).
  • Chatelain D , DuhautP, SchmidtJ et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann. Rheum. Dis. 68 , 84–88 (2009).
  • Salvarani C , CiminoL, MacchioniP et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthr. Rheum. 53 , 293–297 (2005).
  • Loddenkemper T , PankajP, KatzanI, PlantGT. Risk factors for early visual deterioration in temporal arteritis. J. Neurol. Neurosurg. Psych.78 , 1255–1259 (2007).
  • Nesher G , BerkunY, MatesM et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 83 , 114–122 (2004).
  • Gonzalez-Gay MA , Garcia-PorruaC, LlorcaJ et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine 79 , 283–292 (2000).
  • Schmidt WA , KrauseA, SchickeB, KuchenbeckerJ, Gromnica-IhleE. Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis? Rheumatology48 , 383–385 (2009).
  • Dejaco C , DuftnerC, CimminoMA et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann. Rheum. Dis. 70 , 447–453 (2011).
  • Salvarani C , CantiniF, BoiardiL, HunderGG. Laboratory investigations useful in giant cell arteritis and Takayasu‘s arteritis. Clin. Exp. Rheumatol.21(Suppl. 32) , S23–S28 (2003).
  • Macchioni P , CatanosoMG, PipitoneN, BoiardiL, SalvaraniC. Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology48 , 1566–1569 (2009).
  • Jiménez-Palop M , NaredoE, HumbradoL et al. Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica. Ann. Rheum. Dis. 69 , 879–882 (2010).
  • Aschwanden M , KestenF, SternM et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2 × 11 arterial regions. Ann. Rheum. Dis. 69 , 1356–1359 (2010).
  • Bley TA , MarklM, SchelpM et al. Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment. Rheumatology 47 , 65–67 (2008).
  • Ray JG , MamdaniMM, GeertsWH. Giant cell arteritis and cardiovascular disease in older adults. Heart91 , 324–328 (2005).
  • Le Page L , DuhautP, SeydouxD et al. Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG). Rev. Med. Interne. 27 , 98–105 (2006).
  • Borg FA , DasguptaB. Peripheral arterial disease in polymyalgia rheumatica. Arthr. Res. Ther.11 , 111 (2009).
  • Ji J , LiuX, SundquistK, SundquistJ, HemminkiK. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology49 , 1158–1163 (2010).
  • Anderson LA , PfeifferRM, LandgrenO, GadallaS, BerndtSI, EngelsEA. Risks of myeloid malignancies in patients with autoimmune conditions. Br. J. Cancer100 , 822–828 (2009).
  • Hill CL , ColeA, RischmuellerM et al. Risk of cancer in patients with biopsy-proven giant cell arteritis. Rheumatology 49 , 756–759 (2010).
  • Kermani TA , SchäferVS, CrowsonCS et al. Malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthr. Care. Res. 62 , 149–154 (2010).
  • Gonzalez-Gay MA , Lopez-DiazMJ, Martinez-LadoL et al. Cancer in biopsy-proven giant cell arteritis. A population-based study. Semin. Arthr. Rheum. 37 , 156–163 (2007).
  • Proven A , GabrielSE, OrcesC, O‘FallonWM, HunderGG. Glucocorticoid therapy in giant cell arteritis: duration and treatment outcomes. Arthr. Rheum.49 , 703–708 (2003).
  • Gabriel SE , SunkuJ, SalvaraniC, O‘FallonWM, HunderGG. Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthr. Rheum.40 , 1873–1878 (1997).
  • Gonzalez-Gay MA , Garcia-PorruaC, Vazquez-CarunchoM, DababnehA, HajeerA, OllierWE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J. Rheumatol.26 , 1326–1332 (1999).
  • Hoes JN , JacobsJW, VerstappenSM, BijlsmaJW, Van der Heijden GJ. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann. Rheum. Dis.68 , 1833–1838 (2009).
  • Crow RW , KatzBJ, WarnerJE et al. Giant cell arteritis and mortality. J. Gerontol. A Biol. Sci. Med. Sci. 64 , 365–369 (2009).
  • Pipitone N , BoiardiL, BajocchiG, SalvaraniC. Long-term outcome of giant cell arteritis. Clin. Exp. Rheumatol.24(2 Suppl. 41) , S65–S70 (2006).
  • Luqmani RA , SuppiahR, GraysonPC, MerkelPA, WattsR. Nomenclature and classification of vasculitis – update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS). Clin. Exp. Immunol.164(Suppl. 1) , 11–13 (2011).
  • Spies CM , CutoloM, StraubRH, BurmesterGR, ButtgereitF. More night than day – circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J. Rheumatol.37 , 894–899 (2010).
  • Hagihara K , KawaseI, TanakaT, KishimotoT. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J. Rheumatol.37 , 1075–1076 (2010).
  • Seitz M , ReichenbachS, BonelHM, AdlerS, WermelingerF, VilligerPM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. Swiss. Med. Wkly141 , w13156 (2011).
  • Piggott K , DengJ, WarringtonK et al. Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation 123 , 309–318 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.